交银国际每日晨报-20260311

Group 1: 和黄医药 - The company is expected to return to a growth trajectory in 2H25, with a significant rebound in tumor product revenue, increasing by 16% compared to 1H25 [1] - Sales of furmonertinib in overseas markets are projected to rise by 22% year-on-year and 25% quarter-on-quarter in 2H25 [1] - The company has reduced R&D and SG&A expenses by 30% and 9% respectively in 2025, achieving a net profit of $457 million, indicating sustainable profitability [1] Group 2: ATTC Platform - The ATTC platform is anticipated to have a breakthrough year, with HMPL-A251 and HMPL-A580 entering global Phase I trials, and HMPL-830 expected to submit IND applications in 2H26 [2] - Short-term catalysts include the results of global Phase III SAFFRON and Chinese Phase III SANOVO studies for savolitinib, and NDA submissions for various indications [2] - Revenue forecasts for 2026-28 have been raised, with a target price adjustment to HKD 36.60, maintaining a buy rating [2] Group 3: 宁德时代 - The company reported strong annual performance, with revenue of RMB 423.7 billion in 2025, a year-on-year increase of 17%, and a net profit growth of 42.3% to RMB 72.2 billion [3] - The gross margin and net margin for 2025 were 26.3% and 17.0% respectively, with a notable increase in Q4 gross margin to 28.2% [3] - The company’s battery production capacity reached 772 GWh in 2025, with a capacity utilization rate of 96.9%, significantly up from 76.3% in 2024 [4] Group 4: Industry Outlook - The global smartphone and PC shipment volumes are expected to decline by 11% in 2026, indicating a challenging market environment [8] - The semiconductor sector remains promising, with TSMC reporting a 22% year-on-year revenue growth in February 2026, suggesting resilience in the industry [9] - The technology sector is experiencing increased volatility, but the fundamentals of AI remain unchanged, providing potential investment opportunities [7]